Skip to main content
. 2008 Jun 14;14(22):3490–3496. doi: 10.3748/wjg.14.3490

Figure 5.

Figure 5

Antiviral susceptibility of an HBV isolate cloned from a patient with lamivudine resistance. An HBV isolate amplified from the sera of patients failing in lamivudine therapy was cloned into the pHY106 vector and analyzed in vitro. Lane 1-4: transfected cells treated with 0.01, 0.1, 1 and 10 μmol/L of adefovir; Lane 5-8: transfected cells treated with 0.01, 0.1, 1 and 10 μmol/L of lamivudine.